Dronabinol suspension 25 mg/ml

Dronabinol is an oily cannabis oleoresin solution, an extract based on a "discontinued refined cannabis oleoresin DAC" with medium chain triglycerides in the pharmacy.

Dronabinol can be prescribed in three different standardized formulations:

• Dronabinol oily drops 25 mg/ ml (NRF 22.8.).
• Dronabinol capsules 2.5 mg/5 mg/ 10 mg (NRF 22.7.)
• Ethanolic dronabinol solution 10 mg/ml for inhalation (NRF 22.16.)

No usable statements on indications for the use of cannabis flowers, cannabis extract or pure substances can be found. There are clear reasons for this.

On a scientific basis, there are no confirmed indications for the use of cannabis. Cannabis does not rank first in a single indication. It has also often been tried as an additive to first-line therapies without stringent results.

Undoubtedly, there is a vast amount of experience reports and success stories etc., whose motivations raise further questions. But one thing is certain: Since the middle of the 19th century there have been attempts in various fields to establish cannabis as a medicine. Until today, the scientific data situation is very poor and cannot justify the medical use.

Cannabis products, especially those containing tetrahydrocannabiol (THC), have a certain reputation in the treatment of appetite disorders and nausea/vomiting, mostly in connection with malignant diseases and their targeted chemotherapy, for the improvement of typical side effects, for example.

Cannabidiol , which is not subject to narcotic prescription regulations, has shown effects in spasticity, e.g. in multiple sclerosis. This substance lacks its own risk of addiction. All indications in pain therapy prove to be problematic. The study situation is also very weak here.

Among other things, as an antiemetic, appetite stimulant or muscle relaxant in multiple sclerosis in particularly justified cases.

1 ml of NRF 22.8. formulation contains 25 mg of dronabinol (other ingredients: medium chain triglycerides, palmitoyl ascorbic acid).

Oily dronabinol drops were first monographed in 2001 as NRF Prescription 22.8. In 2012, the mass-based percentage concentration 2.5% (25 mg/g) was changed to the volume-based concentration (25 mg/ml). Due to the different density of the neutral oil from one, the active substance concentration is now slightly higher, but this has no effect on the therapeutic efficacy. With the supplementary delivery 2013/1, the production of the oily solution was further optimized.

Dronabinol is subject to narcotics law.